Tazverik (Tazemetostat) – Sarcoma | HongKong DengYue Medicine

Tazemetostat Application Scope

• Indicated for the treatment of epithelioid sarcoma (soft tissue sarcoma subtype)

• Also approved in some regions for relapsed/refractory follicular lymphoma with EZH2 mutation (not the focus here)

Tazemetostat Characteristics

• Ingredients:

  • Active: Tazemetostat

  • Excipients: Standard pharmaceutical excipients

• Properties:​

  • Oral selective EZH2 inhibitor

  • White to off-white film-coated tablets

• Packaging Specification:​

  • 200 mg tablets

  • Common package: 240 tablets/bottle

• Storage:​

  • Store at 20–25 °C (room temperature), excursions permitted 15–30 °C

  • Keep tightly closed, protect from moisture

• Expiry Date: 24 months (bottle unopened)

• Executive Standard: ​Meets FDA / EMA / ICH pharmaceutical quality standards

• Approval Number:

  • US FDA approval (NDA 213400, 2020)

  • EU EMA conditional approval (2020)

• Date of Revision: Latest label update: 2024

• Manufacturer: Epizyme, Inc. (a subsidiary of Ipsen)

Guidelines for the Use of Tazverik

• Dosage and Administration:

  • Recommended Dose: 800 mg orally twice daily (four × 200 mg tablets)

  • Administration: Swallow tablets whole, do not crush or chew

  • Missed Dose:​ If a dose is missed, take the next dose at the regular time; do not double dose

• Adverse Reactions:

  • Common Adverse Reactions:

    • Fatigue

    • Nausea

    • Decreased appetite

    • Abdominal pain

    • Constipation

  • Serious Adverse Reactions:

    • Secondary malignancies (e.g., T-cell lymphoblastic lymphoma, MDS/AML)

    • Severe anemia, thrombocytopenia

    ​

• Contraindications: Known hypersensitivity to Tazemetostat or excipients

• Precautions:

  • Monitor blood counts regularly

  • Embryo-fetal toxicity risk (avoid during pregnancy)

  • Consider contraception during treatment and for a period after

Tazemetostat Interactions

• Substrate of CYP3A; avoid strong/moderate CYP3A inhibitors and inducers

• May affect hormonal contraceptives efficacy

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.